Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Galena Biopharma, Inc. (SLS : NSDQ)
 
 • Company Description   
SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.46 Daily Weekly Monthly
20 Day Moving Average: 203,946 shares
Shares Outstanding: 20.54 (millions)
Market Capitalization: $71.05 (millions)
Beta: 1.74
52 Week High: $15.08
52 Week Low: $2.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 13.82% 28.18%
12 Week -41.36% -35.53%
Year To Date -37.43% -20.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7 TIMES SQUARE SUITE 2503
-
NEW YORK,NY 10036
USA
ph: 646-200-5278
fax: 441-400-2875
ir@sellaslife.com http://www.sellaslifesciences.com
 
 • General Corporate Information   
Officers
Angelos M. Stergiou - Chief Executive Officer and President
Jane Wasman - Chairman
John T. Burns - Chief Accounting Officer;Vice President
David Scheinberg - Director
Robert Van Nostrand - Director

Peer Information
Galena Biopharma, Inc. (CORR.)
Galena Biopharma, Inc. (RSPI)
Galena Biopharma, Inc. (CGXP)
Galena Biopharma, Inc. (BGEN)
Galena Biopharma, Inc. (GTBP)
Galena Biopharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81642T209
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 20.54
Most Recent Split Date: 11.00 (0.02:1)
Beta: 1.74
Market Capitalization: $71.05 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.78 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 17.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -556.25%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -82.46%
vs. Previous Quarter: -%
ROE
03/31/22 - -166.08
12/31/21 - -75.88
09/30/21 - -61.06
ROA
03/31/22 - -108.41
12/31/21 - -55.78
09/30/21 - -42.37
Current Ratio
03/31/22 - 1.67
12/31/21 - 4.63
09/30/21 - 5.45
Quick Ratio
03/31/22 - -
12/31/21 - 4.63
09/30/21 - 5.45
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -1,216.45
12/31/21 - -275.47
09/30/21 - -187.73
Book Value
03/31/22 - 0.20
12/31/21 - 1.28
09/30/21 - 1.68
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.07
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 6.85
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©